Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | GPR3 | P46089 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.32 |
| ▸ | ABAT | P80404 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzaldehyde SCHEMBL18301495 | 0.89 | ALDH1A1 (0.44) | CYP2A6GPR3ALDH1A1KCNH2ACHE | |
| SCHEMBL6847822 | 0.85 | CYP2A6 (0.41) | CYP2A6ALDH1A1TYRSTSCYP2A13 | |
| SCHEMBL2780476 | 0.81 | CYP2A6 (0.52) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| SCHEMBL4830852 | 0.81 | ALDH1A1 (0.42) | CYP2A6ALDH1A1TYRSTSCYP2A13 | |
| SCHEMBL27942473 | 0.79 | CYP2A6 (0.50) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| Iodide SCHEMBL15412173 | 0.79 | CYP2A6 (0.50) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| Iodide SCHEMBL15009902 | 0.79 | CYP2A6 (0.50) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| Bromide SCHEMBL1885936 | 0.79 | CYP2A6 (0.50) | CYP2A6ALDH1A1TYRCYP2A13HSD17B10 | |
| Trifluoromethanesulfonic Acid SCHEMBL17477312 | 0.78 | APOBEC3A (0.54) | GPR3KCNH2ACHE | |
| Trifluoromethanesulfonic Acid SCHEMBL18796033 | 0.76 | ALDH1A1 (0.34) | GPR3ALDH1A1KCNH2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139352-A1 | HER2 BINDERS | GE Precision Healthcare LLC | 2024-05-02 | — | — | US | disclosed |
| US-11633507-B2 | HER2 binders | GENERAL ELECTRIC COMPANY (US) | 2023-04-25 | — | — | US | disclosed |
| WO-2022191759-A1 | A POLYMER-BASED CARBONYL SCAVENGER FOR DETECTION AND TREATMENT OF ISCHEMIC INJURIES | Cremed AB (publ) (SE) | 2022-09-15 | — | — | WO | disclosed |
| EP-4031146-A1 | POSITRON EMISSION TOMOGRAPHY GUIDED DELIVERY OF MITOCHONDRAL COMPLEX I INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-27 | — | — | EP | disclosed |
| EP-3183236-B1 | METHOD FOR THE PRODUCTION OF 18F-LABELED ACTIVE ESTERS AND THEIR APPLICATION EXEMPLIFIED BY THE PREPARATION OF A PSMA-SPECIFIC PET-TRACER | MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WSS (DE) | 2022-04-20 | — | — | EP | disclosed |
| EP-3957332-A1 | RADIOLABELED HER2-BINDING PEPTIDE CONJUGATES | General Electric Company (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3936155-A1 | RADIOLABELED HER2-BINDING PEPTIDE CONJUGATES | General Electric Company (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-2654803-B1 | RADIOLABELED HER2-BINDING PEPTIDE CONJUGATES | GEN ELECTRIC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210170057-A1 | HER2 BINDERS | GEN ELECTRIC (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2021055814-A1 | POSITRON EMISSION TOMOGRAPHY GUIDED DELIVERY OF MITOCHONDRAL COMPLEX I INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20120165650-A1 | HER2 BINDERS | GENERAL ELECTRIC COMPANY (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2424573-A2 | LABELED MOLECULAR IMAGING AGENTS, METHODS OF MAKING AND METHODS OF USE | General Electric Company (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8124725-B2 | PDGF-Rβ binders | GENERAL ELECTRIC COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2381966-A2 | PDGF-R BINDERS | General Electric Company (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010125068-A2 | LABELED MOLECULAR IMAGING AGENTS, METHODS OF MAKING AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100272641-A1 | LABELED MOLECULAR IMAGING AGENTS, METHODS OF MAKING AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100196254-A1 | METHOD FOR THE DIRECT ELUTION OF REACTIVE 18F FLUORIDE FROM AN ANION EXCHANGE RESIN IN AN ORGANIC MEDIUM SUITABLE FOR RADIOLABELLING WITHOUT ANY EVAPORATION STEP BY THE USE OF STRONG ORGANIC BASES | TRASIS S.A. (BE) | 2010-08-05 | — | — | US | disclosed |
| WO-2010079079-A2 | PDGF-Rβ BINDERS | GENERAL ELECTRIC COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20090191124-A1 | PDGF-RBeta BINDERS | GENERAL ELECTRIC COMPANY (US) | 2009-07-30 | — | — | US | disclosed |
| WO-2001085221-A2 | ASSESSING LEVELS OF O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE IN VIVO | DUKE UNIVERSITY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272641-A1 | LABELED MOLECULAR IMAGING AGENTS, METHODS OF MAKING AND METHODS OF USE | SLC7A11, SLC3A2, SLC1A2 | CYP2A6 4852/4885GPR3 1064/4885ALDH1A1 1956/4885 |
| US-20240139352-A1 | HER2 BINDERS | ERBB2, EGFR, ERBB3 | CYP2A6 4515/4885GPR3 1005/4885ALDH1A1 4867/4885 |
| US-20210170057-A1 | HER2 BINDERS | ERBB2, EGFR, ERBB3 | CYP2A6 4515/4885GPR3 1005/4885ALDH1A1 4867/4885 |
| US-11633507-B2 | HER2 binders | ERBB2, EGFR, ERBB3 | CYP2A6 4515/4885GPR3 1005/4885ALDH1A1 4867/4885 |
| US-20090191124-A1 | PDGF-RBeta BINDERS | PDGFRB, PDGFA, PDGFRA | CYP2A6 4841/4885GPR3 371/4885ALDH1A1 2996/4885 |
| US-20120165650-A1 | HER2 BINDERS | ERBB2, EGFR, ERBB3 | CYP2A6 4505/4885GPR3 589/4885ALDH1A1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.